Condition category
Mental and Behavioural Disorders
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status

Plain English Summary

Background and study aims
Dementia is a common condition in the aging population. People with dementia have difficulties with mental processes such as memory, language, reasoning and identifying people and objects, which become progressively worst over time. In 2009 the UK government introduced the establishment of memory services in each health locality so that people experiencing symptoms of dementia can access expert diagnosis and help. The drive for earlier and better diagnosis continues, and was emphasised in the Prime Ministers Challenge on dementia. However the availability of services following early diagnosis has not kept pace. Some memory services provide assistance following diagnosis but others offer little more than medication. This may be because until recently, people only received help in the later stages of the condition or that some felt that nothing could be done to stop the condition after a person had been diagnosed. This view is now changing due to the availability of medication to alleviate symptoms combined with a growing societal movement to raise awareness and promote living well with dementia. Additionally there is a recent realisation that people with the condition can be helped to be independent for longer. Nevertheless, extent of unmet need among those who receive an early diagnosis is significant. This project involves examining the effectiveness of an intervention called Journeying through Dementia for those who are in the early stages of dementia. This program has been developed to help people to self-manage their condition and live their lives. The aim of this study is to explore the effectiveness and cost-effectiveness of the Journeying through Dementia program.

Who can participate?
Patients in the early stages of dementia. Participants can also choose for their supporter e.g. family member or friend (sometimes referred to as a carer) to also participate but this is not essential.

What does the study involve?
Participants are randomly allocated to one of two groups. Those in the first group continue to receive usual care for the duration of the study. Those in the second group also continue to receive their usual treatment as well as the Journeying through Dementia program. This consists of 12 1.5-hour long weekly group sessions and 4 individual sessions, all with trained NHS Facilitators. As part of the sessions people explore self-management techniques, with an emphasis on re-engagement with hobbies and interest. At the start of the study and then after eight and twelve months, participants in both groups complete a number of questionnaires in order to assess their quality of life and self-management skills.

What are the possible benefits and risks of participating?
The main benefit everyone participating in the trial will receive is the knowledge that they are supporting research which will help inform how to improve support to people in the early stages of their dementia. Those attending the Journeying through Dementia intervention may have additional benefits such as an improvement in self-management, however at this stage it is not known if the program is beneficial. There are no known risks involved with participating.

Where is the study run from?
10 NHS trusts across the North and East Midlands of England (UK)

When is the study starting and how long is it expected to run for?
December 2015 to May 2019

Who is funding the study?
National Institute for Health Research (UK)

Who is the main contact?
Mrs Alexis Foster

Trial website

Contact information



Primary contact

Mrs Alexis Foster


Contact details

School of Health and Related Research
University of Sheffield
Regent Court
Regent Street
S1 4DA
United Kingdom
+44 1142 226129

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

A randomised controlled trial of the clinical and cost-effectiveness of the Journeying through Dementia intervention compared to usual care


Study hypothesis

The aim of this study is to evaluate the effectiveness and cost-effectiveness of a self-management group intervention called Journeying through Dementia, for people in the early stages of dementia.

Ethics approval

Leeds East National Research Ethics Service Board, 01/07/2016, ref: 16/YH/0238

Study design

Randomised; Interventional; Design type: Treatment, Education or Self-Management, Psychological & Behavioural, Complex Intervention

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Specialty: Dementias and neurodegeneration, Primary sub-specialty: Dementia; UKCRC code/ Disease: Neurological/ Other disorders of the nervous system


Participants will be randomised on a 1:1 basis using a centrally based computer programme.

Intervention group: Participants receive the Journeying through Dementia intervention a well as usual care. The intervention consists of 12 weekly facilitated group sessions with 8-12 participants (all in the early stages of dementia) over 12 successive weeks, occasionally there may be a week’s break, for example due to a bank holiday.

As part of the intervention, each participant also receives four individual sessions with one of the two facilitators to pursue their individual goals. The first individual session takes place before the commencement of the group and introduces the participant to one of the facilitators and enables discussion about their forthcoming involvement. The other three sessions are spaced over the 12 weeks including one at the end of the group sessions.
The content of the intervention includes (but is not limited to) the following topics:
1. Ways of thinking about dementia:
What is dementia, effects on everyday life, challenging stereotypes, sharing coping strategies
2. Keeping physically well
Relationship between physical and mental wellbeing, embedded health activity in everyday life, diet
3. Memory
Strategies to aid memory, impact on everyday life and learn and practice new techniques
5. Keeping mentally well
Relationship between anxiety and memory and dementia and stress).
6. Endings
Celebration of achievements and how to move forward Maybe use bullet points under each heading rather than brackets?

There is flexibility within the intervention to select different topics and explore topics in the level of detail dictated by the group for example some groups may spend more time on memory with another group spending more time on keeping mentally well.. One essential component is enactment of activities, particularly in the community with participants being encouraged to support each other.
Participants are able to invite a supporter (e.g. family member, friend or neighbour) to participate in the group during sessions 1, 6 and 12, and in the individual sessions if the participant finds this helpful in achieving their goals. This is optional, e.g they do not have to bring along anyone. Nor does it have to be the same person each time or the participating supporter (if there is one).
The intervention is facilitated by two relevant NHS staff members experienced with working with people with dementia. Facilitators need to be at least a Band 3 on the Agenda for Change scale. Examples of relevant staff include nurses, occupational therapists, psychologists, social workers, occupational therapy assistants, assistant psychologists and support workers. Facilitators do not have to be registered health care professionals (HCPS). Additional staff will be trained in the intervention to provide cover for annual leave and sickness absence.
Facilitators at each site will initially receive a two day training course from Dr Claire Craig who devised the intervention. They will then be supported and supervised within their trust by someone experienced in supervision. This will usually be a HCP or social care professional who is a Band 7 on the NHS Agenda for Change scale. For example, someone who is a clinical psychologist or occupational therapist. The supervisors will receive supervision from a member of the trial team.

Control group: Participants receive treatment as usual for the duration of the study.

Both groups will be followed-up for a year, with outcome measure collection at 8 and 12 months post-randomisation.

Intervention type



Drug names

Primary outcome measures

Dementia related quality of life is measured using the DEMQOL questionnaire at baseline and 8 months.

Secondary outcome measures

1. Dementia related quality of life measures using the DEMQOL questionnaire at baseline and 12 months.
2. Mood, specifically symptoms of depression is measured using the Patient Health Questionnaire (PHQ-9) at baseline and 8 months
3. Mood, specifically symptoms of anxiety is measured using the Generalized Anxiety Disorder 7 questionnaire (GAD-7) at baseline and 8 months
4. Quality of life is measured using the EQ-5D-5L questionnaire at baseline, 8 and 12 months
5. Self-efficacy (sense of control of one’s life) is measured using the General Self-Efficacy Scale at baseline and 8 months
6. Having the skills to self-manage is measured using the Self-Management Ability Scale at baseline and 8 months
7. A person’s wellbeing is measured using the Diener’s Flourishing Scale at baseline and 8 months
8. A person’s ability to perform functional tasks is measured using the Instrumental Activities of Daily Living at baseline and 8 months
9. Health and social care service use including medication is measured using the Health and Social Care Resource Use Questionnaire a, 8 and 12 months. This is to inform the cost effectiveness analysis
10. Family and friends' ability to support someone with dementia is being measured by the Sense of Competency in Caregiving questionnaire administered at baseline and 8 months to people supporting the participant

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

People with dementia:
1. People diagnosed with dementia for example Alzheimer’s disease, vascular dementia or mixed Alzheimer’s/vascular dementia
2. A Mini Mental State Examination (MMSE) score of 18 or over (conducted less than 2 months pre consent)
3. Can make informed decisions (assessed by the Capacity Assessment Form)
4. Living in the community or in sheltered accommodation, alone or with others
5. Able to converse and communicate in English
6. Willing to engage in a 12 week group self-management intervention

Supporters (carers of a person with dementia):
1. Aged 18 years or older
2. Named by the person with dementia as their supporter
3. Able to converse and communicate in English
4. Ability to give informed consent

Participant type


Age group




Target number of participants

Planned Sample Size: 486; UK Sample Size: 486

Participant exclusion criteria

People with dementia:
1. Not been diagnosed with a form of dementia
2. Being in more moderate stages of dementia. Measured by having a MMSE score of < 18
3. Is assessed as lacking capacity (assessed by the Capacity Assessment Form)
4. Living in residential or nursing care
5. Not able to converse or communicate in English
6. Is taking part in any other pharmacological or psychosocial intervention studies

1. Under 18 years old
2. The person with dementia they provide support to is not participating in the trial
3. Unable to converse or communicate in English
4. Unnot able to give informed consent

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Sheffield Health and Social Care NHS Foundation Trust
Old Fulwood Road
S10 3TH
United Kingdom

Trial participating centre

Bradford and District Care Trust
Fieldhead House 2-8 St Martins Avenue
United Kingdom

Trial participating centre

Leeds and York NHS Partnership Trust
2150 Century Way
LS15 8ZB
United Kingdom

Trial participating centre

Nottinghamshire Healthcare NHS Foundation Trust
Duncan Macmillan House Porchester Road
United Kingdom

Trial participating centre

Leicestershire NHS Partnership Trust Riverside House
Bridge Park Plaza Bridge Park Road Thurmaston
United Kingdom

Trial participating centre

Rotherham, Doncaster and South Humber NHS Trust
Woodfield House Tickhill Road Site Weston Road Balby
United Kingdom

Trial participating centre

South West Yorkshire NHS Foundation Trust
Fieldhead Ouchthorpe Lane
United Kingdom

Trial participating centre

Tees, Esk and Wear NHS Foundation Trust
West Park Hospital Edward Pease Way
United Kingdom

Trial participating centre

Humber NHS Foundation Trust
Willerby Hill Beverley Road
HU10 6ED
United Kingdom

Sponsor information


Sheffield Health & Social Care NHS Foundation Trust

Sponsor details

Fulwood House
Old Fulwood Road
S10 3TH
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

National Institute for Health Research

Alternative name(s)


Funding Body Type

government organisation

Funding Body Subtype

Federal/National Government


United Kingdom

Results and Publications

Publication and dissemination plan

The findings of the trial will be actively publicised and disseminated. The main trial findings are likely to be published in the summer of 2019.

IPD Sharing plan:
The datasets generated during and/or analysed during the current study are/will be available upon request from the Chief Investigator: Professor Gail Mountain (

Intention to publish date


Participant level data

Available on request

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes